Skip to main content
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2015;15(5):591–597. doi: 10.3233/CBM-150499

TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients

Yan Song 1, Dan Liu 1, Guoping He 1,*
PMCID: PMC12965439  PMID: 26406948

Abstract

BACKGROUND: The significance of transketolase-like enzyme 1 (TKTL1) and p63 in the clinical progression and prognosis of gastric cancer patients has not been established.

OBJECTIVE: This study investigated the expression of TKTL1 and p63 in gastric cancer and their clinical significance.

METHODS: TKTL1 and p63 expression in 101 gastric cancer tissue specimens and 25 normal gastric mucosa tissues were detected by immunohistochemistry (IHC).

RESULTS: The percentage of positive TKTL1 and p63 expression in gastric carcinomas was significantly higher than that in normal gastric mucosa tissues (P < 0.05). Positive TKTL1 and p63 expression significantly correlated with larger tumor size, deeper invasion, higher TNM stage, and lymph node metastasis (P< 0.05). The expression of TKTL1 significantly correlated with p63 expression in gastric cancer tissues (r = 0.476, P < 0.01). Univariate analysis revealed that positive TKTL1 and/or positive p63 expression correlated significantly with shorter survival and lower 5-year survival rate (P = 0.001). Cox multivariate analysis demonstrated that expression of TKTL1 and p63 is an independent prognostic factor (P < 0.05) in gastric cancer.

CONCLUSIONS: Both TKTL1 and p63 are independent prognostic factors of the poor outcome of gastric cancer patients.

Keywords: TKTL1, p63, gastric cancer, prognosis

Full Text

The Full Text of this article is available as a PDF (817.8 KB).


Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES